Ralph Demasi

Ralph Demasi

UNVERIFIED PROFILE

Are you Ralph Demasi?   Register this Author

Register author
Ralph Demasi

Ralph Demasi

Publications by authors named "Ralph Demasi"

Are you Ralph Demasi?   Register this Author

44Publications

1026Reads

40Profile Views

Ribavirin concentration determines treatment success of first-generation DAA-based chronic HCV therapy.

Antivir Ther 2016 17;21(2):153-9. Epub 2015 Sep 17.

Department of Pharmacy, Radboud university medical center, Nijmegen, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3851/IMP2994DOI Listing
January 2018

Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection.

New Microbiol 2017 Jan 9;40(1):19-26. Epub 2017 Jan 9.

National Institute for Infectious Diseases "L. Spallanzani" I.R.C.C.S, 292 Via Portuense, 00149 Rome, Italy.

View Article

Download full-text PDF

Source
January 2017

Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.

J Clin Gastroenterol 2015 Apr;49(4):336-44

*Department of Medicine and Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL †Duke Clinical Research Institute, Durham ‡University of North Carolina at Chapel Hill, Chapel Hill, NC §University of Pennsylvania School of Medicine, Philadelphia, PA ∥Department of Medicine, University of Florida, Gainesville, FL ¶California Pacific Medical Center, San Francisco, CA #Vertex Pharmaceuticals Incorporated, Cambridge, MA **Janssen Research & Development, Titusville, NJ ††Royal Free and University College, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MCG.0000000000000150DOI Listing
April 2015

When can HIV clinical trials detect treatment effects on drug resistance?

Int J STD AIDS 2015 Mar 29;26(4):268-78. Epub 2014 May 29.

Janssen, Titusville, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0956462414536885DOI Listing
March 2015

RE: Non-specific effects of co-administration of live measles, yellow fever and pentavalent vaccines on mortality?

Vaccine 2014 May 25;32(23):2667. Epub 2014 Mar 25.

Clinical Biostatistics, Janssen Research and Development LLC, Titusville, NJ 08560, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2014.03.034DOI Listing
May 2014

Week 96 outcomes of patients with less treatment experience versus more treatment experience receiving etravirine in the DUET trials.

Curr HIV Res 2012 Apr;10(3):256-61

Janssen Services, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/157016212800618110DOI Listing
April 2012

Does earlier HIV RNA suppression provide long-term benefits?

AIDS 2010 Jun;24(10):1591-3

Chelsea and Westminster Hospital, London UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0b013e32833ad933DOI Listing
June 2010

Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration.

Pharmacotherapy 2006 Dec;26(12):1679-86

Trimeris, Inc., Morrisville, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1592/phco.26.12.1679DOI Listing
December 2006

Seeking ethical designs for HIV clinical trials in treatment-experienced patients: an industry perspective.

AIDS Res Hum Retroviruses 2006 Nov;22(11):1110-2

Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/aid.2006.22.1110DOI Listing
November 2006

Prognostic staging of extensively pretreated patients with advanced HIV-1 disease.

HIV Clin Trials 2005 Nov-Dec;6(6):281-90

St. Paul's Hospital, University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1310/0XH7-F2V2-1K0R-NU2WDOI Listing
May 2006

Discordant conclusions from HIV clinical trials--an evaluation of efficacy endpoints.

Antivir Ther 2005 ;10(3):367-74

Department of Pharmacology, University of Liverpool, Liverpool, UK.

View Article

Download full-text PDF

Source
June 2005

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.

Nat Rev Drug Discov 2004 Mar;3(3):215-25

Trimeris Inc., 4727 University Drive, Durham, North Carolina 27707, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd1331DOI Listing
March 2004